A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal
Open Access
- 29 May 2012
- journal article
- case report
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 6 (5) , e1544
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countriesThe Analyst, 2010
- Impact of poor-quality medicines in the ‘developing’ worldTrends in Pharmacological Sciences, 2010
- The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, IndiaTropical Medicine & International Health, 2009
- Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2008
- Comparison between Quantitative Nucleic Acid Sequence-Based Amplification, Real-Time Reverse Transcriptase PCR, and Real-Time PCR for Quantification ofLeishmaniaParasitesJournal of Clinical Microbiology, 2008
- Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal – the challenges for diagnosis and treatmentTropical Medicine & International Health, 2008
- Sodium stibogluconate cardiotoxicity and safety of genericsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2003
- Visceral leishmaniasis control: a public health perspectiveTransactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate.The American Journal of Tropical Medicine and Hygiene, 1998
- History of Kala-Azar in India.1947